Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Asian Patients With FGFR/RET-Altered Solid Tumors
CTR20160272Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erdafitinib in non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC), gastric cancer (GC), esophageal cancer, cholangiocarcinoma (CCA), sponsored by Johnson & Johnson. Started Jul 2017; status: completed.
02
Drugs
erdafitinib
03
Conditions
non-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)gastric cancer (GC)esophageal cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on CTR20160272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160272.